Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
1. The regulation of cell therapy
- Prof. Moutih Rafei
-
2. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
3. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
4. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
5. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
6. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
7. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
8. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
9. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
11. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
12. MassBank development and future
- Dr. Emma L. Schymanski
-
13. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
14. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
16. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
17. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
18. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
19. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
20. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
21. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
22. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
23. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
24. Combating the HIV epidemic
- Prof. William Blattner
-
25. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
26. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
27. Pediatric cancer testing
- Prof. Joshua Schiffman
-
28. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
29. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
30. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
31. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
Topics Covered
- The effect of Group A streptococcal infections on the behaviour of children
- The problem of diagnosis in PANDAS
- Potential mechanisms underlying PANDAS and the role of the immune system
- Current therapeutic interventions and potential future ones
- The importance of developing better diagnostic tools
Biography
P. Patrick Cleary is an Emeritus Professor of Microbiology at the University of Minnesota. Streptococci are masters of immune avoidance. S. pyogenes, the most common cause of sore throat, are also responsible for serious diseases such as rheumatic fever, heart disease, and flesh eating wound infections. Over many years his research investigated the molecular and cellular processes that lead to these infections. He discovered the streptococcal C5a peptidase, which is now a leading candidate for vaccine development. Most recently his work has focused on the T cell response to streptococcal infections and autoimmune neuropathology.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Cleary, P.P. (2018, April 1). PANDAS: a potential link between group A streptococcal infections and neurological disorders [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/VUNQ4760.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. P. Patrick Cleary, Lecturer, shared royalty payments from sales of lecture series.
Audio Interview
PANDAS: a potential link between group A streptococcal infections and neurological disorders
Published on April 1, 2018
25 min
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Cleary, thank you for sparing the time today to speak to us.
As I understand it,
the position is the group A streptococcal infections can produce
an immune response that in turn has a pathologic effect on neuronal tissue.
Have I got it right?
Prof. Cleary: Yes, that's correct. In fact,
we've known this for probably 70 or 80 years,
in the days when there was rheumatic fever
in Britain and in the US and the developed world.
One of the complications of rheumatic fever is Sydenham chorea,
which is uncontrolled muscle movements and contractions,
and we've known about that for a long time.
But I think what you're probably referring to is a newer,
more recently described syndrome.
The acronym for this syndrome has been termed PANDAS,
and there's a more general term, PANS.
PANS, the acronym means Pediatric Acute Onset of Neuropsychiatric Syndrome and PANDAS,
sort of a subgroup of this,
is pediatric autoimmune neuropsychiatric disorder
associated with streptococcus infection.
You can understand why we use acronyms after hearing those long names.
So, we've known for some time that following group A strep infections,
not just any strep but strep pyogenes or group A strep,
we can find antibody in the blood of patients who
have these neurological disorders that react with brain proteins.
In fact, some of these antibodies even react with dopamine receptors,
Hide